Vol 8, No 3 (2004)
Editorial
Published online: 2004-06-04
Treatment of arterial hypertension in patients with chronic pulmonary diseases
Andrzej Tykarski, Katarzyna Kostka-Jeziorny
Nadciśnienie tętnicze 2004;8(3):147-157.
Vol 8, No 3 (2004)
Artykuły redakcyjne
Published online: 2004-06-04
Abstract
This article presents a review of English-language literature
pertaining to drug therapy for systemic high blood pressure in
patients with pulmonary diseases. The concomitant presence of arterial hypertension and chronic airway obstruction (asthma or COPD) is not unusual. Hypertension is the most
common comorbid disease in COPD patients. The antihypertensive
agents reviewed include: diuretics, calcium antagonists, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, β-adrenergic blocking agents, α-blockers and other classes. A wide variety of antihypertensive drugs with different mechanism of action is now available.
Many antihypertensive drugs can affect airway function, the treatment of hypertension in patients with airway dysfunction is complex. For example, β-adrenergic blocking agents can cause bronchoconstriction, because β2-receptors are widely distributed in airway smooth muscles. Beta-blockers can cause severe bronchoconstriction even in subjects with mild asthma. Angiotensin-converting enzyme inhibitors may
cause cough and excerbate or even induce asthma; however angiotensin II type I antagonists do not cause caugh. So it seems that not all antihypertensive drugs are equally safe in patients with systemic arterial hypertension and concurrent
airway dysfunction. Based on the reviewed literature, we suggest
that calcium blockers or angiotensin II receptor antagonists are the first choice drugs for these patients.
Abstract
This article presents a review of English-language literature
pertaining to drug therapy for systemic high blood pressure in
patients with pulmonary diseases. The concomitant presence of arterial hypertension and chronic airway obstruction (asthma or COPD) is not unusual. Hypertension is the most
common comorbid disease in COPD patients. The antihypertensive
agents reviewed include: diuretics, calcium antagonists, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, β-adrenergic blocking agents, α-blockers and other classes. A wide variety of antihypertensive drugs with different mechanism of action is now available.
Many antihypertensive drugs can affect airway function, the treatment of hypertension in patients with airway dysfunction is complex. For example, β-adrenergic blocking agents can cause bronchoconstriction, because β2-receptors are widely distributed in airway smooth muscles. Beta-blockers can cause severe bronchoconstriction even in subjects with mild asthma. Angiotensin-converting enzyme inhibitors may
cause cough and excerbate or even induce asthma; however angiotensin II type I antagonists do not cause caugh. So it seems that not all antihypertensive drugs are equally safe in patients with systemic arterial hypertension and concurrent
airway dysfunction. Based on the reviewed literature, we suggest
that calcium blockers or angiotensin II receptor antagonists are the first choice drugs for these patients.
Keywords
pulmonary disease; antihypertension drugs; COPD; asthma; arterial hypertension
Title
Treatment of arterial hypertension in patients with chronic pulmonary diseases
Journal
Arterial Hypertension
Issue
Vol 8, No 3 (2004)
Article type
Editorial
Pages
147-157
Published online
2004-06-04
Bibliographic record
Nadciśnienie tętnicze 2004;8(3):147-157.
Keywords
pulmonary disease
antihypertension drugs
COPD
asthma
arterial hypertension
Authors
Andrzej Tykarski
Katarzyna Kostka-Jeziorny